Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Biologic Response Modifiers Among Continually Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Kinase Inhibitors Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Miscellaneous Biologic Nonblood Products Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Monoclonal Antibodies Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Other Immunomodulators Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2006

* Small cell = less than 11.
Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2007

* Small cell = less than 11.
Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2008

* Small cell = less than 11.
Annual Utilization of Other Immunosuppressives Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of BCG Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
BCG = Bacillus Calmette-Guerin.
Annual Utilization of Bevacizumab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Bortezomib Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Cyclosporine Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Imatinib Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Rituximab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.
Annual Utilization of Trastuzumab Among Continuously Enrolled Medicare Parts A and B Fee-for-Service Population, by Hospital Referral Region, 2009

* Small cell = less than 11.